Cephalon Sparlon Additional Pre-Approval Safety Study Recommended To Assess Skin Reaction Risk

FDA’s Psychopharmacologic Drugs Advisory Committee rules safety for modafinil product in children with attention deficit/hyperactivity disorder has not been adequately demonstrated.